All In Biotech

Free tool

FAERS Monitor: Epkinly

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761324 or its brand name (Epkinly, Epcoritamab-Bysp). Reports on generic versions are filed under their own applications.

Reports

1,338

Serious

1,237

92% of reports

Hospitalization

316

Death reported

442

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • cytokine release syndrome463
  • diffuse large b-cell lymphoma251
  • diffuse large b-cell lymphoma refractory235
  • pyrexia148
  • immune effector cell-associated neurotoxicity syndrome108
  • malignant neoplasm progression104
  • neutrophil count decreased58
  • cytomegalovirus infection reactivation56
  • covid-1954
  • platelet count decreased45
  • hypogammaglobulinaemia43
  • pneumonia39
  • death38
  • cytomegalovirus infection36
  • off label use31

Reports by year received

View as table
YearReports
2023104
2024580
2025410
2026244

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,821 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
diffuse large b-cell lymphoma refractorySignal2355193.34526.7913,359
diffuse large b-cell lymphomaSignal251529.3472.3127,573
cytokine release syndromeSignal463371.4344.6166,880
immune effector cell-associated neurotoxicity syndromeSignal108291.9243.230,466
cytomegalovirus infection reactivationSignal56201.8155.910,853
hypogammaglobulinaemiaSignal43103.677.14,239
cytomegalovirus infectionSignal3634.124.71,123
neutrophil count decreasedSignal5822.417.41,165
malignant neoplasm progressionSignal10416.013.31,451
pyrexiaSignal1486.75.8727
platelet count decreasedSignal456.65.0211
covid-19Signal544.83.7162
pneumonia391.91.416
death380.70.55
off label use310.60.411

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.